Antiviral treatment study for children with chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This study looks at how well antiviral medicines work in children with chronic hepatitis B. It may help doctors find better ways to treat children who are starting treatment or who have been on treatment for a while.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 1 and 12 years old (for those starting treatment) or between 3 and 12 years old (for those already on treatment).
- Child has had hepatitis B for more than 6 months (for those starting treatment).
- Child has not received antiviral treatment before (for those starting treatment).
- Child has been on antiviral medicine for more than 1 year and is currently taking it (for those already on treatment).
- Child has not used interferon in the past 6 months (for those already on treatment).
- Child's hepatitis B virus level is undetectable and HBsAg is low (for those already on treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests antiviral medicine in babies under 1 year old who have hepatitis B. The goal is to see if early treatment can help clear the virus and protect the liver.
This study tests a medicine called peginterferon alfa-2b to see if it can help children with chronic hepatitis B achieve a functional cure, meaning the virus stays under control. If your child has hepatitis B, this treatment might improve their chances of clearing the infection.
This study tests whether adding a second medicine to the standard hepatitis B treatment helps young children clear the virus better. It may help improve liver health and reduce long-term risks.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This study compares two treatments for children aged 3 to 6 with chronic hepatitis B. One group gets the standard medicine entecavir, and the other gets entecavir plus a medicine that helps the immune system fight the virus (peginterferon). The goal is to see if the combination works better.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.